Skip to main content
. 2015 Oct 15;10(10):e0140479. doi: 10.1371/journal.pone.0140479

Fig 8. Antitumor activity in various mouse xenograft models after treatment with ARQ 092 or ARQ 751.

Fig 8

(A) AN3CA xenograft model treated with ARQ 092, (B) AN3CA xenograft model treated with ARQ 751, (C) KPL-4 xenograft model treated with ARQ 092, (D) ZR-75-1 xenograft model treated with ARQ 092, (E) KPL-4 xenograft model treated with ARQ 092 as a single agent or combined with trastuzumab or paclitaxel, (F) A PDX melanoma model (ST052C) that contained Braf V600E and PIK3CA (H1047R) mutations treated with ARQ 092 as a single agent or combined with trametinib.